ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,370.33
-0.55%
Dow Jones
39,667.10
-0.52%
Gold vs US Dollar
2,388.085
-1.38%
Brent Oil
81.705
-0.90%
Bitcoin
69,527.06
-0.86%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. CRISPR Therapeutics AG (CRSP)

  7. CRISPR Therapeutics AG (CRSP) News

CRISPR Therapeutics (CRSP)

CRISPR Therapeutics AG
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CRSP
DateTimeSourceHeadlineSymbolCompany
09/05/202413:30GlobeNewswire Inc.CRISPR Therapeutics to Present at the Bank of America Securities Health Care ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
08/05/202421:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRSPCRISPR Therapeutics AG
08/05/202421:00GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
08/05/202412:00GlobeNewswire Inc.CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing ApproachNASDAQ:CRSPCRISPR Therapeutics AG
22/04/202421:30GlobeNewswire Inc.CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingNASDAQ:CRSPCRISPR Therapeutics AG
03/04/202413:00GlobeNewswire Inc.CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
01/04/202413:00GlobeNewswire Inc.CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingNASDAQ:CRSPCRISPR Therapeutics AG
13/03/202412:30GlobeNewswire Inc.CRISPR Therapeutics Proposes New Appointment to the Board of DirectorsNASDAQ:CRSPCRISPR Therapeutics AG
21/02/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
21/02/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
21/02/202412:50Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CRSPCRISPR Therapeutics AG
21/02/202412:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRSPCRISPR Therapeutics AG
21/02/202412:30GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CRSPCRISPR Therapeutics AG
16/02/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
15/02/202421:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
15/02/202413:30GlobeNewswire Inc.CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership SummitNASDAQ:CRSPCRISPR Therapeutics AG
13/02/202413:44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CRSPCRISPR Therapeutics AG
13/02/202413:30GlobeNewswire Inc.CRISPR Therapeutics Announces $280 Million Registered Direct OfferingNASDAQ:CRSPCRISPR Therapeutics AG
13/02/202411:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRSPCRISPR Therapeutics AG
13/02/202407:30GlobeNewswire Inc.European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)NASDAQ:CRSPCRISPR Therapeutics AG
31/01/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
29/01/202421:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
29/01/202421:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CRSPCRISPR Therapeutics AG
18/01/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
16/01/202422:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CRSPCRISPR Therapeutics AG
16/01/202421:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRSPCRISPR Therapeutics AG
16/01/202421:01GlobeNewswire Inc.CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta ThalassemiaNASDAQ:CRSPCRISPR Therapeutics AG
10/01/202416:36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CRSPCRISPR Therapeutics AG
08/01/202412:00GlobeNewswire Inc.CRISPR Therapeutics Highlights Strategic Priorities and 2024 OutlookNASDAQ:CRSPCRISPR Therapeutics AG
03/01/202413:30GlobeNewswire Inc.CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CRSPCRISPR Therapeutics AG
 Showing the most relevant articles for your search:NASDAQ:CRSP

Your Recent History

LSE
VAST
Vast Resources
LSE
POLX
Polarean Imaging
LSE
GGP
Greatland Gold
LSE
ZED
Zenova
LSE
SCLP
Scancell
LSE
POS
Plexus
LSE
PHE
Powerhouse Energy
LSE
AGL
Angle
LSE
RKH
Rockhopper Exploration
LSE
TERN
Tern
LSE
LLOY
Lloyds Banking
LSE
KEFI
Kefi Gold And Copper
LSE
AAZ
Anglo Asian Mining
LSE
CHLL
Chill Brands
LSE
GKP
Gulf Keystone Petroleum
LSE
TW.
Taylor Wimpey
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved